AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases VANCOUVER, British Columbia & NEW HAVEN, Conn.–(BUSINESS WIRE)–Dec. 1, 2022– AbCellera (Nasdaq: ABCL)...
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT — Data Demonstrates that HPA-1a Alloimmunization can be Prevented with Prophylactic Administration of...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical...
HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM RESULTS AT ASH 2022 FOR NOVEL T CELL ENGAGER HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with...
Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022 -Data demonstrating novel platform to measure protease activity accurately differentiates patients with hepatocellular carcinoma (HCC) vs. patients...
Recent Comments